Table 5 Measures adopted in European studies on patterns of care for breast, colorectal, lung, and prostate cancer, according to year of publication and to the conclusions drawn by their Authors
From: Overuse in cancer care: do European studies provide information useful to support policies?
Measures | Year of publication | Authors’ conclusions | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
≤ 2010 N (%) | 2011–2012 N (%) | 2013–2014 N (%) | 2015–2016 N (%) | Total N (%) | No explicit statement N (%) | Underuse N (%) | Overuse N (%) | Under and overuse N (%) | Total N (%) | ||
Generic | N % | 16 (55.2) (33.3) | 8 (32) (16.7) | 12 (48) (25) | 12 (80) (25) | 48 (51) (100) | 24 (69) (50) | 17 (51.5) (35.4) | 5 (41.7) (10.4) | 2 (14.3) (4.2) | 48 (51) (100) |
Oriented towards underuse | N % | 6 (20.7) (25) | 8 (32) (33.3) | 9 (36) (37.5) | 1 (7) (6.7) | 24 (25.5) (100) | 8 (23) (33) | 16 (48.5) (67) | 0 (0) (0) | 0 (0) (0) | 24 (25.5) (100) |
Oriented towards overuse | N % | 7 (24.1) (31.8) | 9 (36) (40.9) | 4 (16) (18.2) | 2 (13) (9.1) | 22 (23.5) (100) | 3 (8) (13.6) | 0 (0) (0) | 7 (58.3) (31.8) | 12 (85.7) (54.5) | 22 (23.5) (100) |
Total | N % | 29 (100) (31.2) | 25 (100) (25.8) | 25 (100) (26.9) | 15 (100) (16.1) | 94 (100) (100) | 35 (100) (36.6) | 33 (100) (35.5) | 12 (100) (12.9) | 14 (100) (15) | 94 (100) (100) |